Crossject (ALCJ.PA) Stock Price
Crossject Price
Over the last 14 years Crossject grew revenue by 24.1% annually, reaching 4.12 M EUR. For Crossject, the net margin of -310.9% is down versus -203.2% a few years ago. The consensus 12-month price target for Crossject is 4.39 EUR, about 217.8% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.
Crossject stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Crossject over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Crossject stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Crossject's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Crossject Price |
|---|---|
| 9/11/2026 | 1.38 EUR |
| 9/10/2026 | 1.38 EUR |
| 9/9/2026 | 1.37 EUR |
| 9/8/2026 | 1.38 EUR |
| 9/7/2026 | 1.42 EUR |
| 9/4/2026 | 1.37 EUR |
| 9/3/2026 | 1.41 EUR |
| 9/2/2026 | 1.41 EUR |
| 9/1/2026 | 1.41 EUR |
| 8/31/2026 | 1.53 EUR |
| 8/28/2026 | 1.66 EUR |
| 8/27/2026 | 1.56 EUR |
| 8/26/2026 | 1.58 EUR |
| 8/25/2026 | 1.48 EUR |
| 8/24/2026 | 1.41 EUR |
| 8/21/2026 | 1.41 EUR |
| 8/20/2026 | 1.44 EUR |
| 8/19/2026 | 1.44 EUR |
| 8/18/2026 | 1.45 EUR |
| 8/17/2026 | 1.42 EUR |
| 8/14/2026 | 1.45 EUR |
| 8/13/2026 | 1.43 EUR |
| 8/12/2026 | 1.47 EUR |
| 8/11/2026 | 1.48 EUR |
| 8/10/2026 | 1.49 EUR |
| 8/7/2026 | 1.50 EUR |
| 8/6/2026 | 1.52 EUR |
| 8/5/2026 | 1.50 EUR |
| 8/4/2026 | 1.49 EUR |
| 7/31/2026 | 1.50 EUR |
Crossject Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Crossject Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 1.00 | 1.00 | 1.00 | 3.00 | 2.00 | – | 4.00 | – | – | – | 4.00 | – | 60.00 | 42.00 | 55.00 |
| – | – | – | – | 200.00 | -33.33 | – | – | – | – | – | – | – | – | -30.00 | 30.95 |
| – | -200.00 | -2,200.00 | -2,200.00 | -733.33 | -1,100.00 | – | -550.00 | – | – | – | -525.00 | – | -36.67 | -52.38 | -40.00 |
| -22.00 | -2.00 | -22.00 | -22.00 | -22.00 | -22.00 | -9.00 | -22.00 | -11.00 | -13.00 | -6.00 | -21.00 | -22.00 | -22.00 | -22.00 | -22.00 |
| -2.00 | -5.00 | -5.00 | -7.00 | -8.00 | -12.00 | -9.00 | -11.00 | -11.00 | -13.00 | -11.00 | -14.00 | -12.00 | 36.00 | 45.00 | 60.00 |
| – | -500.00 | -500.00 | -700.00 | -266.67 | -600.00 | – | -275.00 | – | – | – | -350.00 | – | 60.00 | 107.14 | 109.09 |
| -1.00 | -4.00 | -5.00 | -6.00 | -7.00 | -10.00 | -7.00 | -9.00 | -10.00 | -11.00 | -8.00 | -12.00 | -10.00 | 18.00 | 23.00 | 32.00 |
| – | 300.00 | 25.00 | 20.00 | 16.67 | 42.86 | -30.00 | 28.57 | 11.11 | 10.00 | -27.27 | 50.00 | -16.67 | -280.00 | 27.78 | 39.13 |
| 5.28 | 6.57 | 6.59 | 7.70 | 9.08 | 17.94 | 20.31 | 24.07 | 26.18 | 36.68 | 36.49 | 50.26 | 52.26 | 52.26 | 52.26 | 52.26 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Crossject generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Crossject retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Crossject's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Crossject has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Crossject's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Crossject stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Crossject Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Crossject business model & stock analysis
Crossject SWOT Analysis
Strengths
Crossject SA has several strengths that contribute to its competitive advantage in the market. Firstly, the company possesses a unique and innovative drug delivery technology known as Zeneo®, which enables the painless and efficient administration of drugs. This technology offers significant advantages over traditional injection methods, making it a valuable asset for Crossject SA.
Additionally, Crossject SA has a strong intellectual property portfolio, including various patents and trademarks, which provide legal protection and exclusivity for their innovative drug delivery systems. This further strengthens the company's position in the market and acts as a barrier to entry for potential competitors.
Furthermore, the company has formed strategic partnerships with established pharmaceutical companies. These partnerships not only bring financial benefits to Crossject SA but also provide access to a wide range of resources, including expertise, distribution channels, and market opportunities.
Weaknesses
Despite its strengths, Crossject SA also has some weaknesses that need to be addressed. One notable weakness is the relatively limited market presence and brand recognition compared to well-established competitors. This can pose challenges in terms of market penetration and attracting a broad customer base.
Moreover, the production and commercial scale-up of their drug delivery systems may present a weakness. Maintaining a stable and cost-effective production process while meeting the increasing demand can be challenging, especially for a relatively small company like Crossject SA.
Opportunities
The market for innovative drug delivery systems is growing rapidly, driven by the rising demand for easier and less invasive administration methods. Crossject SA can capitalize on this opportunity by leveraging its unique technology and expanding its product portfolio to cater to different therapeutic areas and market segments.
Furthermore, the increasing focus on self-medication and home healthcare presents an opportunity for Crossject SA. Their painless and user-friendly drug delivery systems align well with these trends and can attract a significant customer base seeking convenient and reliable self-administration options.
Threats
Crossject SA faces threats from both existing competitors and potential new entrants in the market. Established pharmaceutical companies may try to imitate or develop similar drug delivery technologies, challenging Crossject SA's competitive advantage. Additionally, evolving regulations and reimbursement policies in the healthcare industry can impact the adoption and commercial success of the company's products.
Moreover, unexpected events such as regulatory setbacks, manufacturing disruptions, or economic downturns can significantly impact the company's operations and financial performance. Crossject SA needs to mitigate these threats through effective risk management strategies and continuous innovation.
Crossject Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Crossject historical P/E ratio, EBIT multiple, and P/S ratio
Crossject annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Crossject shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Crossject forecasts and price targets in September 2026
Analyst Price Targets 2026Crossject shareholder structure
| % | Name |
|---|---|
0.19763% | |
0.00000% | |
0.00000% |
Crossject Beneficial Ownership Filings (SEC 13D/G)
Crossject Executives and Management Board
8 members · avg. age 63 · 0 % women
Management
Dr. Dan Chiche
Chief Medical Officer
Board of Directors
Mr. Philippe Monnot
Chairman of the Supervisory Board
Mr. Patrick Alexandre (60)
Chairman of the Management Board, Co-Founder · since 2012
Mr. Eric Nemeth
Independent Vice Chairman of the Supervisory Board
Mr. Henri De Parseval
Member of the Management Board
Mr. Jean-Francois Loumeau
Member of the Supervisory Board
Dr. Yannick Pletan (72)
Member of the Supervisory Board
Crossject Supply Chain
Frequently asked questions about Crossject
The business model of Crossject SA revolves around the development and commercialization of innovative drug delivery systems. Crossject specializes in needle-free, self-administered emergency treatments for severe medical conditions such as anaphylactic shock and epileptic seizures. The company's proprietary technology, Zeneo®, enables the rapid and efficient delivery of drugs through the skin, ensuring quick and reliable therapy in critical situations. By combining ease of use, portability, and safety, Crossject aims to revolutionize the field of self-medication. With a focus on achieving market penetration globally, Crossject collaborates with pharmaceutical companies to expand the range of emergency treatments available through its innovative delivery platform.
Crossject SA is primarily active in the pharmaceutical industry.
The main competitors of Crossject SA in the market include companies such as Pfizer, Novartis, Eli Lilly, Sanofi, and Johnson & Johnson.
Crossject SA is a renowned pharmaceutical company that specializes in developing innovative and efficient medical solutions. Founded in [year], the company is based in [location] and has a rich history of successful product development. Crossject SA primarily focuses on the development of advanced and easy-to-use medical injection systems, which aim to enhance patient convenience and treatment experiences. With a strong commitment to research and development, Crossject SA collaborates with experts in the healthcare industry to bring cutting-edge solutions to the market. The company has gained a reputation for its dedication to improving medical delivery methods, ensuring safer and more effective treatments for patients worldwide.
Crossject SA has achieved several significant milestones. The company successfully developed an innovative and proprietary needle-free injection system, Zeneo®. This device has the potential to revolutionize the way drugs are administered, providing numerous benefits such as painless injections, rapid drug delivery, and ease of use. Furthermore, Crossject SA has obtained regulatory approval for Zeneo® in Europe and initiated partnerships with major pharmaceutical companies to develop and market various drugs using their advanced technology. These achievements highlight Crossject SA's commitment to revolutionizing drug delivery and position the company as a key player in the pharmaceutical industry.
Crossject SA is primarily present in France, its country of origin. As a biopharmaceutical company, it focuses on developing and commercializing innovative injectable drug device combinations. With its headquarters in Dijon, France, Crossject SA operates in the European Union and has a strong presence in other regions as well. Its mission is to improve the quality of life for patients through its needle-free injection technologies.
Crossject SA represents a set of core values and a corporate philosophy that aligns with their mission. Known for their innovative drug delivery solutions, Crossject SA emphasizes excellence, integrity, and patient-centricity. With a focus on developing needle-free injection systems, the company is committed to providing safe, convenient, and effective medical devices to improve patient outcomes. Crossject SA's corporate philosophy centers around technological advancement, collaboration, and market leadership. Through their dedication to research, development, and strategic partnerships, Crossject SA continues to push boundaries in the pharmaceutical industry, delivering innovative solutions and driving positive change for patients globally.
Analysts currently set an average price target of 4.11 EUR for the Crossject stock (median: 4.39 EUR), implying +198.1 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Crossject stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Crossject to generate revenue of 60.80 M EUR and earnings per share of 0.36 EUR.
The Crossject share (ALCJ.PA) is listed on 3 stock exchanges, including: Frankfurt (74C.F), Paris (ALCJ.PA).
Crossject SA is an innovative healthcare company based in France that specializes in the development and manufacturing of injectable drug systems. The company aims to create new solutions for fast, easy, and safe drug administration. Crossject has been listed on the stock market since 2014 and has branches in France, Switzerland, and the USA. The business model of Crossject is based on the development and commercialization of innovative autoinjectors that contribute to improving the treatment of chronic and acute diseases. The company focuses on four main areas: diabetes, anaphylaxis, pain management, and emergency medicine. Crossject is currently developing a range of products in these areas that meet the requirements of patients, doctors, and hospitals. The products offered by Crossject include the ZMI Autoinjector System, the ZENEO Autoinjector System, and the COLLECTJECT Autoinjector System. The ZMI Autoinjector System is an easy-to-use system that administers medications in precise doses. This system is ideal for diabetics and provides a fast and effective solution for insulin administration. The ZENEO Autoinjector System has been specifically designed for use in patients with anaphylaxis. It is easy to use and provides fast and precise administration of adrenaline. The COLLECTJECT Autoinjector System is a disposable autoinjector specifically designed for emergencies. It can be used to administer various medications such as painkillers and antibiotics. Crossject's core competence is its proprietary Needle Free Injection technology, which allows for the administration of medications without penetrating the skin with a needle. This technology is not only efficient and painless, but also reduces the risk of needlestick injuries and infections. Crossject has successfully integrated this technology into its autoinjectors and is currently able to offer a variety of medications in injectable form. Crossject has developed a comprehensive strategy for the commercialization of its autoinjectors. The company works closely with its customers to better understand the needs of patients and doctors and adapt its products accordingly. Crossject has also formed partnerships with major pharmaceutical companies such as Sanofi and CDM Lavoisier to market its products and build a global presence. Overall, Crossject's business model demonstrates that the company is innovative and focused on the needs of patients and doctors. Crossject aims to revolutionize the healthcare industry through the development of new autoinjectors and the introduction of new medications. The company also strives to expand its global presence and strengthen its partnerships with pharmaceutical companies to better market its products.
The expected revenue of Crossject is 60.80 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Crossject is 18.67 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Crossject is currently 3.86. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Crossject stock.
The price-to-sales ratio (P/S) of Crossject is currently 1.19. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Crossject stock.
The Eulerpool Quality Score for Crossject is 2/10.
The ISIN of Crossject is FR0011716265. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Crossject is A1XEH4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Crossject is ALCJ.PA. The ticker symbol is used to trade Crossject shares on the stock exchange.
Crossject paid dividends every year for the past 0 years.
Crossject is assigned to the 'Health' sector.
The dividends of Crossject are distributed in EUR.
Crossject stock
Crossject Peer Group
Crossject Ticker
Crossject FIGI
All fundamentals and in-depth analysis of Crossject
Our stock analysis for Crossject stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Crossject. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.